Schroder Investment Management Group’s PTC Therapeutics PTCT Stock Holding History

Schroder Investment Management Group’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.27M	Sell	101,429 -33,539	-25%	-$2.42M	0.01%	704
2026 Q1	$8.86M	Buy	134,968 +62,371	+86%	+$4.42M	0.01%	691
2025 Q4	$5.53M	Buy	72,597 +38,475	+113%	+$2.8M	﹤0.01%	736
2025 Q3	$2.07M	Buy	+34,122	New	+$1.78M	﹤0.01%	924
2024 Q4	–	Sell	-51,293	Closed	-$1.93M	–	1236
2024 Q3	$1.93M	Buy	+51,293	New	+$1.72M	﹤0.01%	944
2024 Q1	–	Sell	-17,000	Closed	-$469K	–	1236
2023 Q4	$469K	Buy	+17,000	New	+$389K	﹤0.01%	1097
2016 Q1	–	Sell	-24,322	Closed	-$788K	–	1209
2015 Q4	$788K	Buy	+24,322	New	+$716K	﹤0.01%	941

Other funds holding PTCT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Schroder Investment Management Group's PTCT Position: Q2 2026 in Review

Schroder Investment Management Group reduced its PTC Therapeutics (PTCT) stake by 25% in Q2 2026, selling an estimated $2.42M and leaving 101,429 shares worth $8.27M. The position accounts for 0.01% of the portfolio, ranked #704.

Schroder Investment Management Group first reported a position in PTCT in Q4 2015 and has held it in 7 quarters since. The position peaked at $8.86M in Q1 2026. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

Schroder Investment Management Group held 101,429 shares of PTC Therapeutics worth $8.27M as of Q2 2026.
Schroder Investment Management Group sold 33,539 PTC Therapeutics shares in Q2 2026, an estimated $2.42M.
PTC Therapeutics made up 0.01% of Schroder Investment Management Group's portfolio in Q2 2026, its #704 holding.
Schroder Investment Management Group first reported a position in PTC Therapeutics in Q4 2015 and has held it in 7 quarters since.
Schroder Investment Management Group's PTC Therapeutics position peaked at $8.86M in Q1 2026.
382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Schroder Investment Management Group's 13F filing for Q2 2026, filed 13 Aug 2026.